Literature DB >> 6122461

Inhibition of antipyrine metabolism by beta-adrenoceptor antagonists.

N D Bax, M S Lennard, G T Tucker.   

Abstract

1 The effects of two beta-adrenoceptor antagonists (propranolol and metoprolol), and of the beta-adrenoceptor agonist, terbutaline, on the plasma kinetics of antipyrine were studied in five normal subjects. In addition, the influence of propranolol on the clearance of antipyrine to three of its major metabolites was investigated. 2 At the same level of beta-adrenoceptor blockade, assessed by lowering of exercise tachycardia, propranolol decreased antipyrine clearance by 37.3 +/- 9.9 s.d. % (P less than 0.001) and metoprolol decreased it by 18.0 +/- 4.7 s.d. % (P less than 0.01). Terbutaline had no effect on antipyrine clearance. The volume of distribution of antipyrine was unchanged following treatment with all three drugs. 3 Only the metabolic clearance of antipyrine to its 3-hydroxymethyl product was impaired to a statistically significant degree by propranolol. However, four of the five subjects also showed impaired clearance to 4-hydroxyantipyrine and three of the five to norantipyrine after propranolol treatment. In four of the five subjects propranolol lowered the renal clearance of antipyrine. 4 Inhibition of the metabolism of antipyrine by beta-adrenoceptor antagonists may be related to their lipid-solubility and extent of metabolism and is independent of their effect on beta-adrenoreceptors.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6122461      PMCID: PMC1401937          DOI: 10.1111/j.1365-2125.1981.tb01306.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  15 in total

1.  Interaction of a series of beta-adrenergic blocking drugs with rat hepatic microsomal monooxygenase.

Authors:  R M Facino; R Lanzani
Journal:  Pharmacol Res Commun       Date:  1979-05

2.  Effect of different beta-adrenergic receptor blocking agents on hexobarbital induced narcosis in mice.

Authors:  K Hermansen
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1969

3.  Pharmacokinetic interaction between propranolol and chlorpromazine in schizophrenic patients.

Authors:  M Peet; D N Middlemiss; R A Yates
Journal:  Lancet       Date:  1980-11-01       Impact factor: 79.321

4.  Studies on the different metabolic pathways of antipyrine in man. I. Oral administration of 250, 500 and 1000 mg to healthy volunteers.

Authors:  M Danhof; D D Breimer
Journal:  Br J Clin Pharmacol       Date:  1979-12       Impact factor: 4.335

5.  Effect of propranolol on morphine metabolism.

Authors:  S F Brunk; M Delle; W R Wilson
Journal:  Clin Pharmacol Ther       Date:  1974-12       Impact factor: 6.875

6.  Effect of propranolol on pharmacokinetics and acute electrocardiographic changes following intravenous quinidine in humans.

Authors:  H R Ochs; D J Greenblatt; E Woo; K Franke; T W Smith
Journal:  Pharmacology       Date:  1978       Impact factor: 2.547

7.  Studies on the different metabolic pathways of antipyrine in rats: influence of phenobarbital and 3-methylcholanthrene treatment.

Authors:  M Danhof; D P Krom; D D Breimer
Journal:  Xenobiotica       Date:  1979-11       Impact factor: 1.908

8.  [On the metabolism of antipyrine (phenazone) in man (author's transl)].

Authors:  E Zietz; M Eichelbaum; H J Dengler; G Spiteller
Journal:  Arzneimittelforschung       Date:  1978

9.  Assay of antipyrine and its primary metabolites in plasma, saliva and urine by high-performance liquid chromatography and some preliminary results in man.

Authors:  M Danhof; E de Groot-van der Vis; D D Breimer
Journal:  Pharmacology       Date:  1979       Impact factor: 2.547

10.  Impairment of antipyrine clearance in humans by propranolol.

Authors:  D J Greenblatt; K Franke; D H Huffman
Journal:  Circulation       Date:  1978-06       Impact factor: 29.690

View more
  48 in total

1.  Effect of ciprofloxacin on antipyrine pharmacokinetics and metabolism in rats.

Authors:  A Anadón; M R Martinez-Larrañaga; M C Fernandez; M J Diaz; P Bringas
Journal:  Antimicrob Agents Chemother       Date:  1990-11       Impact factor: 5.191

2.  Pharmacokinetic interaction between propranolol and the HMG-CoA reductase inhibitors pravastatin and lovastatin.

Authors:  H Y Pan; J Triscari; A R DeVault; S A Smith; D Wang-Iverson; B N Swanson; D A Willard
Journal:  Br J Clin Pharmacol       Date:  1991-06       Impact factor: 4.335

3.  Testing for bimodality in frequency distributions of data suggesting polymorphisms of drug metabolism--histograms and probit plots.

Authors:  P R Jackson; G T Tucker; H F Woods
Journal:  Br J Clin Pharmacol       Date:  1989-12       Impact factor: 4.335

4.  The effect of combined therapy on the pharmacokinetics and pharmacodynamics of verapamil and propranolol in patients with angina pectoris.

Authors:  J C McCourty; J H Silas; G T Tucker; M S Lennard
Journal:  Br J Clin Pharmacol       Date:  1988-03       Impact factor: 4.335

5.  The impairment of lignocaine clearance by propranolol--major contribution from enzyme inhibition.

Authors:  N D Bax; G T Tucker; M S Lennard; H F Woods
Journal:  Br J Clin Pharmacol       Date:  1985-05       Impact factor: 4.335

6.  Selectivity and dose-dependency of the inhibitory effect of propranolol on theophylline metabolism in man.

Authors:  J O Miners; L M Wing; K J Lillywhite; R A Robson
Journal:  Br J Clin Pharmacol       Date:  1985-09       Impact factor: 4.335

7.  The effect of beta-adrenoceptor antagonists on the pharmacokinetics and pharmacodynamics of warfarin after a single dose.

Authors:  N D Bax; M S Lennard; G T Tucker; H F Woods; N R Porter; R G Malia; F E Preston
Journal:  Br J Clin Pharmacol       Date:  1984-05       Impact factor: 4.335

8.  Lack of effect of atenolol on the pharmacokinetics of theophylline.

Authors:  L A Cerasa; J S Bertino; E A Ludwig; M Savliwala; E Middleton; R L Slaughter
Journal:  Br J Clin Pharmacol       Date:  1988-12       Impact factor: 4.335

9.  Dextromethorphan pretreatment induces antipyrine clearance in the rat.

Authors:  C K Svensson; J A Ware
Journal:  Pharm Res       Date:  1988-07       Impact factor: 4.200

Review 10.  Pyrazolone derivatives.

Authors:  R N Brogden
Journal:  Drugs       Date:  1986       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.